Sequel Med Tech

Executive Summary

Sequel Med Tech is a private US medical device company focused on advancing automated insulin delivery (AID) systems for diabetes management. Founded in 2019 and headquartered in Manchester, New Hampshire, the company has developed and received FDA clearance for its flagship product, the twiist™ AID system, which aims to make advanced insulin therapy more accessible and affordable. The company operates in the competitive diabetes technology market, targeting both Type 1 and Type 2 diabetes patients. With a focus on innovation and user-friendly design, Sequel Med Tech seeks to differentiate through affordability and ease of use, potentially capturing market share from established players. The company's stage is undisclosed, but having a cleared product suggests it is in early commercialization or pre-revenue scaling. Its success hinges on adoption by patients and providers, reimbursement coverage, and the ability to iterate on its platform. Given the growing diabetes epidemic and increasing demand for smart insulin delivery, Sequel Med Tech is well-positioned for growth, though it faces competition from larger players like Insulet and Tandem Diabetes.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance of next-generation twiist system with enhanced algorithms75% success
• Q4 2026Strategic partnership or distribution agreement with a major insulin manufacturer50% success
• Q4 2026Series B or Series C funding round to scale manufacturing and commercialization80% success